jarun011
jarun011 / iStockphoto.com
31 August 2017Americas

Bayer takes pre-emptive strike to protect haemophilia treatment

Bayer HealthCare has filed a lawsuit against Nektar Therapeutics and Baxalta seeking a declaration that a treatment for haemophilia A does not infringe their patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
16 March 2018   A Californian court has rejected a motion to dismiss a lawsuit involving a treatment for haemophilia A, a genetic blood coagulation disorder.
Americas
6 February 2019   A US jury has ordered pharmaceutical company Baxalta Inc. to pay $155 million to Bayer Healthcare following a patent infringement trial.

More on this story

Americas
16 March 2018   A Californian court has rejected a motion to dismiss a lawsuit involving a treatment for haemophilia A, a genetic blood coagulation disorder.
Americas
6 February 2019   A US jury has ordered pharmaceutical company Baxalta Inc. to pay $155 million to Bayer Healthcare following a patent infringement trial.

More on this story

Americas
16 March 2018   A Californian court has rejected a motion to dismiss a lawsuit involving a treatment for haemophilia A, a genetic blood coagulation disorder.
Americas
6 February 2019   A US jury has ordered pharmaceutical company Baxalta Inc. to pay $155 million to Bayer Healthcare following a patent infringement trial.